BMS’ Breyanzi gets FDA accelerated approval for follicular lymphoma
The approval is based on results from open-label, global, multicentre, Phase 2, single-arm TRANSCEND FL study in which…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
16 May 24
The approval is based on results from open-label, global, multicentre, Phase 2, single-arm TRANSCEND FL study in which…
15 May 24
DoH and GSK will work together to maximise the strategic and healthcare impacts of the newly established vaccine…
15 May 24
China’s NMPA approved Nefecon in late 2023 for the treatment of primary IgAN in adults who are at…
15 May 24
GenoBlend is made from premium ingredients, including organic pea protein, organic brown rice protein, organic citrus fibre, and…
15 May 24
Upstaza is a one-time gene replacement therapy intended for patients aged 18 months and older who have a…
15 May 24
The study brings together Verismo's proprietary SynKIR platform and novel CD19 binder to treat CAR-naïve and post-CAR relapsed…
15 May 24
Facility includes new technology platforms, substantially expanding Precision for Medicine's capacity to provide clients with best-in-class laboratory testing…
15 May 24
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced an updated version of its clinical decision support platform,…
14 May 24
Takeda will receive an exclusive option to license ACI-24.060, an active immunotherapy that delays Alzheimer’s disease progression, and…
14 May 24
The partnership will harness AbbVie's psychiatric knowledge and Gilgamesh Pharmaceuticals’ research platform to advance next-gen neuroplastogens for psychiatric…